Patents Examined by Christopher Low
  • Patent number: 5082785
    Abstract: A process of producing 2-keto-L-gulonic acid from sorbose via a recombinant bacteria including expression vectors and probes for producing said recombinant bacteria.
    Type: Grant
    Filed: January 30, 1987
    Date of Patent: January 21, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ronald F. Manning, Maria S. Kahn
  • Patent number: 5082775
    Abstract: The present invention relates to the isolation and restoration of biological activity to inactive proteins, that is solubilizing, renaturing and restoring activity to proteins which have been partially denatured or inactivated, e.g. during their synthesis in a host cell, such as E. coli, or during isolation. In particular this invention relates to both a means for extracting insoluble eukaryotic proteins from bacteria and to an efficient process for producing active chymosin from an insoluble chymosin precursor isolated from genetically engineered bacteria.
    Type: Grant
    Filed: October 28, 1988
    Date of Patent: January 21, 1992
    Assignee: Berlex Laboratories, Inc.
    Inventors: Michael T. McCaman, John F. King
  • Patent number: 5061625
    Abstract: To prepare a microorganism producing .alpha.-galactosidase, not only a DNA containing an .alpha.-galactosidase gene but also a vector which is appropriate to the transformable cells to be used and contains antibiotic resistance genes are completely split with restriction endonuclease Sal I, the fragment of approximately four megadaltons of relative molecular weight is obtained from the fragments of the DNA containing the .alpha.-galactosidase gene, is mixed with the solution of the vector also split with Sal I, and is recombined in the presence of DNA ligase with the formation of a recombinant DNA.
    Type: Grant
    Filed: August 24, 1988
    Date of Patent: October 29, 1991
    Assignee: Boehringer Mannheim GmbH
    Inventors: Ralf Mattes, Klaus Beaucamp
  • Patent number: 5055400
    Abstract: The gene coding for Pasteurella haemolytica leukotoxin can be cloned in a plasmic expressed in Escherichia coli. The leukotoxin gene can be isolated from a clone bank of P. haemolytica. The clone bank is constructed by partial digestion of genomic DNA. The resultant 5 to 10 kilobase-pair fragments are ligated into plasmid vector pBR322. The resultant clones are screened for the production of P. haemolytica soluble antigens by a colony enzyme-linked immunosorbent assay blot method with a rabbit antiserum raised against the soluble antigens. The clones producing P. haemolytica soluble antigens are then analyzed for the production of the leukotoxin by a cytotoxicity assay with cells from a bovine leukemia-derived B-lymphocyte cell line as the target cells. Positive clones are identified, and subsequent restriction analysis of the recombinant plasmids shows the same insert DNA is cloned in the plasmid vector. The DNA sequence analysis of the insert DNA reveals regions coding for the leukotoxin.
    Type: Grant
    Filed: November 26, 1986
    Date of Patent: October 8, 1991
    Assignee: University of Guelph
    Inventors: Reggie Y. C. Lo, Patricia E. Shewen, Craig A. Strathdee
  • Patent number: 5047505
    Abstract: Plasmid pUC8 and DNA coding for hIL-1.beta. are used to construct hybrid plasmids capable of high level expression in E. coli of soluble proteins, including mature hIL-1.beta. and derivatives of mature hIL-1.beta. having amino acid substitutions and insertions at one or all of positions 1 to 4 at the amino terminus. Derivatives of hIL-1.beta. with alterations at the N-terminus have been produced which have either enhanced or decreased bioactivity compared to native monocyte derived hIL-1.beta..
    Type: Grant
    Filed: December 18, 1987
    Date of Patent: September 10, 1991
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: James J. Huang
  • Patent number: 5037744
    Abstract: Human serum albumin is made by culturing a bacterium (e.g. E. coli) capable of providing for the stable maintenance of a plasmid containing an inducible promoter (e.g. P.sub.trp), a ribosome binding site (e.g. that of the CII gene of bacteriophage lambda not containing the t.sub.R1 sequence), and the human serum albumin gene possessing an ATG initiation codon at the 5' end.
    Type: Grant
    Filed: December 13, 1989
    Date of Patent: August 6, 1991
    Assignee: Genetica
    Inventors: Michael Knapp, Georges Brefort, Paolo Sarmientos
  • Patent number: 5028426
    Abstract: A thymidine kinase deficient live deletion mutant of pseudorabies virus is provided. The mutant, designated PRV783 was derived from the live deletion mutant strain 2.4N3A by deleting a 19 bp sequence from the BamHI fragment 11 of strain 2.4N3A into which had been inserted an EcoRI restriction site at a unique cleavage site in fragment 11 for the restriction endonuclease XhoI. The 19 bp deletion encompasses the inserted EcoRI site in fragment 11 of strain 2.4N3A. PRV783 is useful for preparing vaccine compositions to immunize susceptible animals against infection by pseudorabies virus.
    Type: Grant
    Filed: July 28, 1987
    Date of Patent: July 2, 1991
    Assignee: Centraal Diegeneeskundig Instituut
    Inventors: Antonius J. M. Berns, Arnold L. J. Gielkens, Robertus J. M. Moormann
  • Patent number: 5026651
    Abstract: The present invention discloses the isolation and nucleic acid sequence of a cDNA recombinant plasmid insert which contains the entire coding sequence for the human transferrin protein. The predicted amino acid sequence of human transferrin is disclosed as well. The cDNA-bearing recombinant plasmid was selected from a human recombinant clone bank constructed in the plasmid pKT218, a derivative of pBR322. Also disclosed are proposed methods and compositions for constructing a recombinant expression vector whereby one may obtain expression of the recombinant human transferrin protein.
    Type: Grant
    Filed: April 25, 1985
    Date of Patent: June 25, 1991
    Assignee: Board of Regents, The University of Texas System
    Inventors: Barbara H. Bowman, Funmei Yang
  • Patent number: 5023183
    Abstract: Entomogenous nematodes can be used as biological insecticides for the control of certain pests. The present invention provides a large-scale production in liquid culture of these entomogenous nematodes using an improved liquid culture medium. The medium uses an emulsifier to provide a well homogenized growth medium. The invention also provides a method of cultivating entomogenous nematodes on a commercial scale, in liquid culture, in fermenters by controlling the agitation rate as a function of oxygen demand.
    Type: Grant
    Filed: November 20, 1987
    Date of Patent: June 11, 1991
    Assignee: Biosys Corporation
    Inventors: Milton J. Friedman, Susan E. Langston, Sonia Pollitt
  • Patent number: 5008371
    Abstract: A biologically active polypeptide, method of obtaining same and use thereof are disclosed. The polypeptide is obtained through steps of cultivating a cell line established from Sarcophaga peregrina embryo to produce the same in a culture medium, as product of the cell line, isolating and purifying the same. The polypeptide shows an anti-virus activity.
    Type: Grant
    Filed: January 22, 1988
    Date of Patent: April 16, 1991
    Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.
    Inventor: Shunji Natori
  • Patent number: 4963489
    Abstract: The present invention relates to a three-dimensional cell culture system which can be used to culture a variety of different cells and tissues in vitro for prolonged periods of time. In accordance with the invention, cells derived from a desired tissue are inoculated and grown on a pre-established stromal support matrix. The stromal support matrix comprises stromal cells, such as fibroblasts, grown to subconfluence on a three-dimensional matrix. Stromal cells may also include other cells found in loose connective tissue such as endothelial cells, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma, etc. The stromal matrix provides the support, growth factors, and regulatory factors necessary to sustain long-term active proliferation of cells in culture. When grown in this three-dimensional system, the proliferating cells mature and segregate properly to form components of adult tissues analogous to counterparts found in vivo.
    Type: Grant
    Filed: September 8, 1988
    Date of Patent: October 16, 1990
    Assignee: Marrow-Tech, Inc.
    Inventors: Gail K. Naughton, Brian A. Naughton
  • Patent number: 4870012
    Abstract: A method for degrading linalool using Pseudomonas strains is described. Also described are novel Pseudomons putida strains which degrade linalool and in some instances geraniol and citronellol. A method for producing 6-methyl-5-heptene-2-one using certain novel strains is also described.
    Type: Grant
    Filed: July 27, 1988
    Date of Patent: September 26, 1989
    Assignee: Microlife Technics, Inc.
    Inventor: Peter A. Vandenbergh
  • Patent number: 4800158
    Abstract: A method for degrading linalool using Pseudomonas strains is described. Also described are novel Pseudomonas putida strains which degrade linalool and in some instances geraniol and citronellol. A method for producing 6-methyl-5-heptene-2-one using certain novel strains is also described.
    Type: Grant
    Filed: March 20, 1986
    Date of Patent: January 24, 1989
    Assignee: Microlife Technics, Inc.
    Inventor: Peter A. Vandenbergh